| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
51,230,000 |
| Market
Cap: |
96.31(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.88 - $1.88 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Jounce Therapeutics is a clinical-stage immunotherapy company focuses on the treatment of cancer by developing therapies that enable the immune system to attack tumors. Co.'s product candidates include: JTX-8064, an antibody that binds to Leukocyte Immunoglobulin Like Receptor B2; Vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of certain T cells commonly found in several solid tumors; Pimivalimab, a clinical-stage anti-PD-1 antibody for potential use in combination with its product candidates; and GS-1811, a monoclonal antibody that depletes T regulatory cells in the tumor microenvironment.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
85,987 |
| Total Buy Value |
$0 |
$0 |
$0 |
$85,958 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
124,313 |
| Total Sell Value |
$0 |
$0 |
$0 |
$167,105 |
| Total People Sold |
0 |
0 |
0 |
4 |
| Total Sell Transactions |
0 |
0 |
0 |
9 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Pfeffer Cary |
Director |
– • – |
2021-03-01 |
4 |
S |
$0.00 |
$0 |
I/I |
(0) |
0 |
|
53% |
|
| Levin Mark J |
10% Owner |
– – • |
2021-03-01 |
4 |
S |
$11.75 |
$17,037,500 |
D/D |
(1,450,000) |
7,750,349 |
|
53% |
|
| Higgons John Duncan |
Director |
– • – |
2021-02-16 |
4 |
AS |
$11.78 |
$2,356 |
D/D |
(200) |
10,113 |
|
-34% |
|
| Murray Richard /ca/ |
CEO and President |
• • – |
2021-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
7,500 |
222,871 |
|
- |
|
| Cole Hugh M |
Chief Business Officer |
• – – |
2021-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
26,700 |
73,889 |
|
- |
|
| Trehu Elizabeth |
Chief Medical Officer |
• – – |
2021-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
22,250 |
93,585 |
|
- |
|
| Drapkin Kimberlee C |
CFO and Treasurer |
• – – |
2021-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
22,250 |
65,431 |
|
- |
|
| Murray Richard /ca/ |
CEO and President |
• • – |
2021-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
215,371 |
|
- |
|
| Cole Hugh M |
Chief Business Officer |
• – – |
2021-01-22 |
4 |
AS |
$11.95 |
$215,100 |
D/D |
(18,000) |
47,189 |
|
-37% |
|
| Cole Hugh M |
Chief Business Officer |
• – – |
2021-01-22 |
4 |
OE |
$4.40 |
$54,750 |
D/D |
10,000 |
65,189 |
|
- |
|
| Murray Richard /ca/ |
CEO and President |
• • – |
2021-01-21 |
4 |
AS |
$12.06 |
$404,227 |
D/D |
(33,518) |
140,371 |
|
-35% |
|
| Murray Richard /ca/ |
CEO and President |
• • – |
2021-01-21 |
4 |
OE |
$0.48 |
$16,089 |
D/D |
33,518 |
173,889 |
|
- |
|
| Higgons John Duncan |
Director |
– • – |
2021-01-21 |
4 |
AS |
$11.11 |
$2,222 |
D/D |
(200) |
10,313 |
|
-35% |
|
| Drapkin Kimberlee C |
CFO and Treasurer |
• – – |
2021-01-21 |
4 |
AS |
$12.00 |
$45,588 |
D/D |
(3,799) |
43,181 |
|
-35% |
|
| Drapkin Kimberlee C |
CFO and Treasurer |
• – – |
2021-01-21 |
4 |
OE |
$2.36 |
$8,966 |
D/D |
3,799 |
46,980 |
|
- |
|
| Higgons John Duncan |
Director |
– • – |
2021-01-20 |
4 |
AS |
$12.00 |
$18,000 |
D/D |
(1,500) |
10,513 |
|
-30% |
|
| Drapkin Kimberlee C |
CFO and Treasurer |
• – – |
2021-01-20 |
4 |
AS |
$10.03 |
$295,198 |
D/D |
(26,201) |
43,181 |
|
-30% |
|
| Drapkin Kimberlee C |
CFO and Treasurer |
• – – |
2021-01-20 |
4 |
OE |
$0.48 |
$15,217 |
D/D |
13,501 |
69,382 |
|
- |
|
| Trehu Elizabeth |
Chief Medical Officer |
• – – |
2021-01-20 |
4 |
AS |
$12.01 |
$78,065 |
D/D |
(6,500) |
71,335 |
|
-30% |
|
| Trehu Elizabeth |
Chief Medical Officer |
• – – |
2021-01-20 |
4 |
OE |
$4.02 |
$26,130 |
D/D |
6,500 |
77,835 |
|
- |
|
| Murray Richard /ca/ |
CEO and President |
• • – |
2021-01-20 |
4 |
AS |
$12.04 |
$198,443 |
D/D |
(16,482) |
140,371 |
|
-30% |
|
| Murray Richard /ca/ |
CEO and President |
• • – |
2021-01-20 |
4 |
OE |
$0.48 |
$7,911 |
D/D |
16,482 |
156,853 |
|
- |
|
| Murray Richard /ca/ |
CEO and President |
• • – |
2021-01-19 |
4 |
AS |
$9.59 |
$383,600 |
D/D |
(40,000) |
140,371 |
|
-18% |
|
| Murray Richard /ca/ |
CEO and President |
• • – |
2021-01-19 |
4 |
OE |
$0.48 |
$19,200 |
D/D |
40,000 |
180,371 |
|
- |
|
| Murray Richard /ca/ |
CEO and President |
• • – |
2021-01-15 |
4 |
AS |
$8.54 |
$256,200 |
D/D |
(30,000) |
140,371 |
|
-13% |
|
158 Records found
|
|
Page 3 of 7 |
|
|
